UPL Limited, the world’s largest producer of mancozeb, has announced a strategic 5 per cent price increase on its mancozeb technical and formulation products across its China operations. The decision, formalized through a price adjustment notice, comes in response to tightening supplies of critical raw materials and evolving global and domestic demand dynamics.

The price revision affects all China-based UPL operations, including its wholly owned subsidiaries and joint ventures—UPL Shanghai Ltd., UPL Jiangsu Ltd., and Beijing Yanhua Yoloo Biotechnology Co., Ltd. The move underscores the rising cost pressures being felt across the agrochemical value chain, particularly for broad-spectrum fungicides like mancozeb, which remains a staple in disease management programs across major crops.

“As input volatility continues across global supply chains, this price adjustment reflects the need to preserve reliability and product quality while navigating heightened procurement costs,” said a senior company official familiar with the development.

The update arrives at a time when agrochemical manufacturers globally are recalibrating pricing models to cope with input scarcity, regulatory shifts, and margin compression. For UPL—a company that operates in over 130 countries with a growing focus on sustainable agtech platforms—the China market remains strategically vital, both as a manufacturing hub and a key demand center.

The company has not indicated any planned revisions outside China as of now, though similar pressures are reportedly building in Southeast Asia and Latin America.

As the global crop protection industry braces for continued volatility in raw material access and cost structures, UPL’s move could signal a broader trend of pricing recalibration across the sector.